key: cord-0854273-2z8i7vwr
authors: Giné, Eva; de la Cruz, Fátima; Jiménez Ubieto, Ana; López Jimenez, Javier; Martín García-Sancho, Alejandro; Terol, M. José; González Barca, Eva; Casanova, María; de la Fuente, Adolfo; Marín-Niebla, Ana; Muntañola, Ana; González-López, Tomás José; Aymerich, Marta; Setoain, Xavier; Cortés-Romera, Montserrat; Rotger, Amanda; Rodríguez, Sonia; Medina Herrera, Alejandro; García Sanz, Ramón; Nadeu, Ferran; Beà, Silvia; Campo, Elías; López-Guillermo, Armando
title: Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial
date: 2022-04-10
journal: J Clin Oncol
DOI: 10.1200/jco.21.02321
sha: 2a6db1ffc8313063c58d4522f539bae124fe0326
doc_id: 854273
cord_uid: 2z8i7vwr

The need for an individualized management of indolent clinical forms in mantle cell lymphoma (MCL) is increasingly recognized. We hypothesized that a tailored treatment with ibrutinib in combination with rituximab (IR) could obtain significant responses in these patients. METHODS: This is a multicenter single-arm, open-label, phase II study with a two-stage design conducted in 12 Spanish GELTAMO sites (ClinicalTrials.gov identifier: NCT02682641). Previously untreated MCL patients with indolent clinical forms defined by the following criteria were eligible: no disease-related symptoms, nonblastoid variants, Ki-67 < 30%, and largest tumor diameter ≤ 3 cm. Both leukemic non-nodal and nodal subtypes were recruited. Patients received ibrutinib 560 mg once daily and a total of eight doses of rituximab 375 mg/m(2). Ibrutinib could be discontinued after 2 years in the case of sustained undetectable minimal residual disease (MRD). The primary end point was the complete response (CR) rate achieved after 12 cycles according to Lugano criteria. RESULTS: Fifty patients with MCL (male 66%; median age 65 years) were enrolled. After 12 cycles of treatment, 42 (84%; 95% CI, 74 to 94) patients had an overall response, including 40 (80%; 95% CI, 69 to 91) with CR. Moreover, undetectable MRD in peripheral blood was achieved in 87% (95% CI, 77 to 97) of cases. At 2 years, 24 of 35 evaluable patients (69%) could discontinue ibrutinib because of undetectable MRD. Four patients had disease progression; three were non-nodal MCL and carried high genomic complexity and TP53 mutations at enrollment. No unexpected toxicity was seen except one patient with severe aplastic anemia. CONCLUSION: Frontline IR combination achieves a high rate of CRs and undetectable MRD in indolent clinical forms of MCL. Discontinuation seems appropriate in cases with undetectable MRD, except for TP53-mutated cases.

Mantle cell lymphoma (MCL) is usually considered an aggressive lymphoid neoplasm; however, some patients show an indolent clinical course with long survival times even in the absence of intensive therapy. 1 In the past two decades, different studies have recognized a molecular subtype known as leukemic non-nodal (nnMCL), because of a clinical presentation mainly characterized by splenomegaly and leukemic involvement without a significant enlargement of lymph nodes, 2,3 often combined with an indolent behavior. These cases have particular biologic features such as mutations in IGHV genes and possibly different cell of origin. [2] [3] [4] [5] From the clinical stand point, asymptomatic patients with MCL, usually with low tumor burden and proliferation, could be managed with observation and deferring therapy until disease progression. [6] [7] [8] [9] [10] [11] [12] In retrospective studies, this approach has been shown to be safe with no compromise for the long-term outcome of the patients. However, there is no consensus on how to define these patients with indolent MCL nor on how to manage them. Regarding treatment, the MCL therapeutic landscape has rapidly evolved in the past few years with the introduction of targeted drugs. 13 Its combinations either with immunochemotherapy or with other targeted approaches in a chemotherapy-free way are currently being extensively investigated in both MCL relapse [14] [15] [16] [17] [18] and frontline. 17, 19, 20 The use of minimal residual disease (MRD), which has demonstrated an outstanding prognostic value in immunochemotherapy-based clinical trials, 21 needs to be evaluated in depth with new targeted therapies in MCL. Nevertheless, it seems reasonable to incorporate this parameter to try to limit the duration of the otherwise indefinite administration of new drugs.

The IMCL-2015 study aimed to evaluate the combination of ibrutinib with rituximab (IR) in the upfront treatment of indolent clinical forms of MCL by means of a MRD-driven approach to limit treatment duration. By using a clinical definition to select indolent MCL cases, we intended to provide an easy ground to allow future comparisons although a deep biologic characterization of these cases should be performed.

The Spanish Lymphoma Group (GELTAMO [Grupo Español de Linfomas y Trasplante Autólogo de MédulaÓsea]) carried out an open-label, multicenter, single-arm, phase II study in patients with untreated indolent clinical forms of MCL. Patients were enrolled in 12 centers according to the following key eligibility criteria: age 18 years or older; confirmed MCL diagnosis according to WHO diagnosis, excluding blastoid variants and/or Ki-67 . 30%; previously untreated; asymptomatic and with an Eastern Cooperative Oncology Group performance status score of 0 or 1; and leukemic non-nodal forms but also other clinical presentations as long as the largest diameter of the lymph nodes did not exceed 3 cm. In addition, stable disease for at least 3 months with no signs of progression or immediate need of treatment was also required (Protocol, online only) The study was approved by the ethics committees of the centers and conducted according to the Declaration of Helsinki and International Conference on Harmonisation guidelines for Good Clinical Practice. All patients provided written informed consent. This trial is registered with Clinical-Trials.gov identifier: NCT02682641.

The GELTAMO-sponsored IMCL-2015 study, NCT02682641 and EudraCT: 2015-004158-17, was first approved by the ethics committee of the Hospital Clínic of Barcelona in January 26, 2016.

Patients received four weekly doses of rituximab at 375 mg/ m 2 intravenously during the first cycle of 28 days (days 1, 8, 15, and 22 of cycle 1) followed by four more doses at day one of every other cycle (cycles 3, 5, 7, and 9) up to a total of eight doses. Ibrutinib was given orally at a fixed continuous dose of 560 mg once daily and discontinued after 2 years of treatment in the case of sustained undetectable MRD (at least for 6 months at two consecutive determinations), otherwise until progression or unacceptable toxicity. Adverse events (AEs) were evaluated according to the Common Toxicity Criteria for adverse Events (CTCAE, version 4.03). The screening workup and the assessment of response after cycle 12 (C12) included a positron emission tomographycomputed tomography (PET-CT), bone marrow (BM) aspirate, and biopsy. Histologic review and peripheral blood (PB) sample collection for genomic studies were centralized at Hospital Clínic of Barcelona. Lugano response criteria were applied and included a central review of PET-CT by the GELTAMO imaging working group. For the detection of MRD, samples of PB and BM were centralized at Hospital Clínico Universitario de Salamanca. EuroMRD protocols 22 were applied for allele-specific oligonucleotide real-time quantitative polymerase chain reaction and when needed, next-generation sequencing-based protocols, 23 to allow at least a sensitivity of 10 25 . Patients were monitored with MRD studies and CT scans every 6 months for a maximum planned follow-up of 7 years. All genetic analyses were CONTEXT Key Objective Indolent clinical forms of mantle cell lymphoma (MCL) could deserve an individualized management. For the first time, the IMCL-2015 evaluates a tailored frontline treatment using ibrutinib in combination with rituximab (IR). In addition, a minimal residual disease (MRD)-driven time-limited treatment is incorporated, which is a clear novelty in this disorder.

The IR is highly active in indolent clinical forms of MCL patients, achieving high rates of complete responses and undetectable MRD, which allows treatment interruption in the majority of responders. Of note, no differences have been observed among non-nodal MCL or conventional MCL molecular subtypes. However, patients with TP53 mutations have a higher risk of early progression and poor survival. performed as previously described 4, 5 and are detailed in the Data Supplement (online only).

The primary end point was the complete response (CR) rate achieved at 12 months of treatment (after completion of C12) according to Lugano criteria in the intention-to-treat population. Secondary end points included the safety and the tolerability of the IR combination, overall response (OR) and the rate of undetectable MRD, progression-free survival (PFS), duration of response, and overall survival (OS).

The hypothesis was that ibrutinib and rituximab combination (IR) would achieve at least a 50% CR rate compared with 30% usually obtained with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. We used Simon's two-stage optimal design with error probabilities a and b of .05 and .2, respectively, to fix the final figure at 50 patients that included a 10% increase because of potential dropouts. The first stage would TP53 mutations corresponded to truncating (three), missense (two), and one splice site mutation; a nnMCL signature was observed in three of the TP53-mutated cases and a cMCL in two cases; all but one case had high genomic complexity. consist of 15 patients. If five or less CRs were observed, the trial had to be terminated; otherwise, recruitment could continue. Nineteen or more CRs in 46 evaluable patients had to be observed to meet the primary end point of the study.

An amendment allowed accepting a response evaluation at 6 months instead of 12 months, by using CT scan and BM aspirate, with the goal of ensuring an adequate treatment activity to justify the movement to stage II without penalizing excessively the recruitment time. All the CRs assessed at Four patients were nonevaluable at 12 months of treatment because of treatment discontinuation: severe aplastic anemia, skin rash, and withdrawal consent because of treatment intolerance and unrelated event with vertebral fractures. 6 months in stage I were later confirmed at 12 months according to the initial description of the protocol. Both primary and safety analyses were performed by intention to treat in all 50 patients included in the study.

Descriptive statistics were used to assess the baseline characteristics of the patients. The survival analysis was performed by the Kaplan-Meier method, and differences were assessed by the log-rank test. P values , .05 were considered statistically significant. All statistical analyses were performed using IBM SPSS version 25 and R version 3.6.0.

Between June 7, 2016, and December 10, 2019, 50 patients with untreated indolent clinical forms of MCL were enrolled in 12 GELTAMO centers to receive the IR combination. Baseline characteristics are summarized in Table 1 . The median observation time from diagnosis to therapy was 7.9 (3-107) months.

Histologic, genetic, and molecular data of 49 patients with available material are detailed in Table 2 and the Data Supplement. As required, no blastoid forms were identified and Ki-67 when evaluable was below 30%, except in two cases (34% and 50%) after centralized review. The L-MCL16 assay 4 could be performed in 31 cases, in which 17 (55%) had the nnMCL gene expression profile and 14 (45%) had a conventional MCL (cMCL) signature. Among patients with a leukemic clinical presentation, with or without splenomegaly or small lymph nodes, 68% had a nnMCL profile. The main initial features according to TP53 mutational status and molecular subtypes are shown in the Data Supplement.

The CONSORT diagram of the patients is shown in Figure 1 . The data cutoff date was May 28, 2021. Stage I of the study completed recruitment of 15 patients in April 2017. When six patients achieved a CR with no early discontinuations, recruitment continued to complete the 50 patients originally planned. Forty-three patients received the eight intended doses of rituximab, and seven patients between four and seven doses. The dose of ibrutinib was reduced in six patients (12%), and four cases (8%) required early discontinuation; thus, at 1 year, 46 patients were receiving ibrutinib treatment.

After 12 cycles of treatment, 46 patients were evaluated according to Lugano criteria. The remaining four patients had early discontinuation between 1.6 and 5.5 months of ongoing treatment because of severe aplastic anemia, accidental vertebral fractures, skin rash, and withdrawal of consent because of treatment intolerance. The centralized evaluation showed 42 of 50 patients (84%; 95% CI, 74 to 94) responding to treatment, with 40 (80%; 95% CI, 69 to 91) patients achieving a CR (Table 3) . No clinical or biologic variables, including Mantle Cell Lymphoma International Prognostic Index (MIPI), b2-microglobulin, molecular subtypes, TP53 mutational status, or high genomic complexity, predicted CR achievement at 12 months. Response rates according to molecular subtypes and TP53 mutational status are listed in Table 3 , and for genomic complexity, in the Data Supplement.

Sequential MRD determinations in PB and BM are detailed in the Data Supplement. After 12 cycles of IR, 40 of 46 evaluable patients (87%; 95% CI, 77 to 97) achieved undetectable MRD in PB and 28 of 43 evaluable patients (65%; 95% CI, 51 to 78) also in BM. Focusing on the 40 patients with CR, MRD was undetectable in PB in 37 of 40 (93%; 95% CI, 86 to 100) assessed patients and also in BM, in 26 of 37 (70%; 95% CI, 55 to 85) patients. No significant differences in terms of molecular response were seen according to the clinicobiologic variables mentioned above.

Thirty-seven patients had reached 24 cycles of ibrutinib. As shown in the CONSORT diagram, two additional patients had discontinued the trial because of disease progression and pancreatic adenocarcinoma, respectively, and seven had not yet reached 24 cycles of therapy. In addition, MRD was under evaluation in two cases. As per protocol, ibrutinib was discontinued in 24 of 35 evaluable cases (69%) because of response with sustained undetectable MRD after C24. Among the 24 patients who have discontinued treatment, three cases stopped ibrutinib earlier because of intolerance and two cases were considered in PR and SD after cycle 12 evaluation, respectively. At the last cutoff, 19 patients continued having undetectable MRD in PB (the maximum MRD follow-up after planned discontinuation was 34 months), whereas five converted to detectable MRD in PB between 3 and 20 months from discontinuation. Only one clinical relapse has been detected after MRD conversion within those 24 patients (Data Supplement).

All four patients with disease progression at the last followup were preceded by persistence or reappearance of detectable MRD in PB. After a median follow-up of 36 months for surviving patients, the estimated PFS at 36 months was 93% (95% CI, 86 to 100; Fig 2A) . Only MIPI and TP53 mutational status showed a significant impact on PFS, with no differences by molecular subtype (nnMCL v cMCL), genomic complexity ( Figures 2B-2E) , or MRD status at C12 (Data Supplement). Multivariate analysis was not performed as the proportional hazards assumption was not met. The event-free survival at 36 months was 76% (95% CI, 64 to 89; Fig 2A) .

Six patients have died so far, four cases because of MCL progression and the other two as a result of pancreatic adenocarcinoma and SARS-CoV-2 infection, respectively. The OS at 36 months was 92% (95% CI, 84 to 100; Fig 2A) . Interestingly, three of the four patients with disease progression had a nnMCL subtype and carried high genomic complexity with TP53 mutations. The remaining case was a cMCL with wild-type TP53 and without genomic complexity. Only one of these patients was eligible for active salvage treatment, but was refractory to different immunochemotherapy and new targeted drugs.

Focusing on the six TP53-mutated cases included in this study, five achieved a CR, including four with undetectable MRD that allowed discontinuation of ibrutinib as per protocol in two cases. All but one of the patients eventually converted to detectable MRD. Clinical progression has been observed in three cases with a median PFS of 38.5 months (95% CI, 37 to 39; v not reached for wild-type TP53 cases; P 5 .0001; Fig 2C) . Three TP53-mutated patients have died because of disease progression in two cases and from SARS-CoV-2 infection in one case that also had detectable MRD. The median OS of TP53-mutated cases was significantly lower than that of wild-type cases (38.5 months; 95% CI, 37 to 39 v not reached, respectively, P 5 .0002).

The most common treatment-related AEs were diarrhea (38%), neutropenia (36%), fatigue (32%), upper respiratory infection (24%), nausea (22%), and arterial hypertension (20%; Table 4 ). Grade $ 3-4 AEs were predominantly hematologic toxicity (22%). At the last cutoff, six patients had discontinued ibrutinib because of intolerance. Atrial fibrillation and stroke were seen in 2 and 1 cases, respectively. Three neoplasms, basocellular carcinoma, pancreatic adenocarcinoma, and bladder carcinoma at 1, 12, and 40 months, from the onset of treatment were observed in two patients. Severe aplastic anemia was observed in one case at 5.5 months of IR treatment. At that time, the patient was in CR by CT imaging, with undetectable MRD in both PB and BM. Despite IR treatment withdrawal, the severe aplasia did not recover and required treatment with antithymocyte globulin followed by allogeneic stem-cell transplantation. The patient is alive and in CR.

The present study shows that the IR combination achieves a high rate of complete and molecular responses as upfront treatment for indolent clinical forms of MCL. This is a MRDdriven study that results in a time-limited treatment with the IR combination for the majority of patients. The discontinuation of ibrutinib therapy after 2 years seems reasonable in this selected population, particularly in patients without TP53 mutation.

The primary end point of the study was met: IR combination proved to be very active in this setting, with 80% of CR at 1 year, including a high proportion of undetectable MRD. Further conclusions regarding the potential effectiveness of this combination in the frontline treatment are limited because of the study design, a nonrandomized phase II study lacking a comparator arm. However, these results compare favorably with what we could expect from established high-dose treatment approaches, indeed with a most favorable toxicity profile. Moreover, these excellent data should be taken with caution as the MCL population herein evaluated was favorably selected and, more importantly, a longer term follow-up is needed to see how sustained such responses are. It is of note that the outstanding efficacy was achieved with only eight doses of rituximab and a MRD-driven duration of ibrutinib. Treatment was limited to 2 years in about 70% of responders. This aspect of the IMCL-2015 study differs from the majority of currently ongoing studies in which new targeted drugs are usually used until disease progression.

By contrast, perhaps a small part of the patients included in the IMCL-2015 study might not have required treatment.

The definition and management of the so-called indolent clinical forms of MCL patients is currently an open question with scarce and mostly retrospective available evidence. 1, [6] [7] [8] [9] [10] [11] [12] 24 Moreover, the different policies in the selection of patients to apply observation and the lack of reliable biomarkers hamper having a benchmark where to make any consistent comparison. In most of these series, [6] [7] [8] [9] [10] [11] [12] a median time to treatment between 1 and 2 years has been described, and only 7% of initially observed cases had longterm observation (. 5 years) in one study. 6 Regarding previously reported experiences with targeted combinations, the IR regimen has already been tested in relapsed/refractory patients with MCL. 14, 18 Although no direct comparison with single-agent ibrutinib is available, the results of the combination seem superior with CR in 58% of cases and a median PFS of 43 months in the absence of unexpected toxicity. 18 The very recently published results for the frontline IR combination in older patients 20 Our study also provides detailed MRD information for the IR combination, to our knowledge, showing for the first time, the possibility of applying a MRD-guided treatment cessation. We observed that molecular responses with IR combination were achieved rapidly, especially in PB, most likely because of rituximab treatment. In some cases, MRD response was achieved over time.

It is an open question whether cases with detectable MRD could have benefited from a longer exposure to rituximab, as disease progression was preceded by detectable MRD in all cases. Despite the fact that the follow-up is still short, many of the patients in whom ibrutinib was stopped after C24 because of sustained undetectable MRD continue in a molecular response for more than 2 years after discontinuation. Overall, these data are very promising and suggest that time-limited MRD-guided treatment with new targeted therapies in MCL is feasible and worth exploring in future studies.

After a median follow-up of 3 years, four clinical progressions (8%) have been observed. Interestingly, three of the four cases had a nnMCL variant and carried high genomic complexity with TP53 mutation, which could explain the poor outcome. However, no significant differences in the outcome have been observed so far between nnMCL and cMCL molecular subtypes or according to genomic complexity. Although the present data indicate a noteworthy activity of the IR combination in TP53-mutated MCL cases in terms of CR, similar to what have been described in other studies using ibrutinib-based combinations in the relapsed and refractory setting, [15] [16] [17] the duration of the responses seems to be lower than that in TP53 wild-type cases, with this translating into a significantly poorer median PFS and OS (Fig 2C and Data Supplement). Thus, in practical terms, TP53-mutated cases seem to be not particularly suitable for IR discontinuation, even with undetectable MRD, since most likely these patients may relapse in a short period of time. Nonetheless, the median PFS and OS observed in our study for TP53-mutated cases are much better than those described in the series of patients treated with an intensive immunochemotherapy approach, including high-dose cytarabine and autologous stem-cell transplantation. 25 This could be explained either by an improved activity of targeted IR treatment over intensive immunochemotherapy in TP53-mutated cases or by a highly selected MCL population with favorable clinical characteristics.

The toxicity seen with the IR combination in first-line was expected, with a predominance of hematologic toxicity, where up to 22% of patients experienced grade 3-4 neutropenia. This figure is superior than that observed with IR in older patients 20 with MCL (8%), and this could be explained by the enriched presence of cases with leukemic involvement in our trial. Gastrointestinal symptoms and fatigue were also frequent, although in general with low or mild intensity, and seemed to be less frequently observed than when the IR combination was given in the relapsed and refractory setting 14 or in frontline in older patients, 20 which could be attributed to the better general condition of our patients. We observed few AEs of special interest such as hypertension or atrial fibrillation. The limited duration of the treatment could also contribute to the few AEs observed and therefore a lower discontinuation from the study than the one observed in older patients with MCL for IR combination. 20 Despite that, up to 12% of patients had to discontinue treatment during follow-up because of ibrutinib intolerance and an additional 8% because of other reasons, including severe aplastic anemia and pancreatic adenocarcinoma, among others. The IMCL-2015 study has shown the high activity, in terms of CR and undetectable MRD, of the upfront IR combination in indolent clinical forms of MCL following a MRDdriven approach to limit the extent of treatment. The duration of molecular and clinical responses after ibrutinib discontinuation will be a key aspect to define the final role of such individualized approaches. Some patients, particularly those with a TP53 mutation, may not be good candidates for treatment discontinuation, even in the case of molecular response. Future randomized studies are guaranteed to explore the final role of targeted therapies in the frontline treatment of patients with MCL. 

The funding for the IMCL-2015 was obtained through unrestricted Janssen Clinical Investigator-Initiated Study (IIS) Research Support. Janssen was not involved in the protocol writing, data collection, and analysis or interpretation of results. Janssen was informed of the development of the IMCL-2015 study and reviewed the manuscript before submission.

Disclosures provided by the authors are available with this article at DOI https://doi.org/10.1200/JCO.21.02321.

The Spanish Lymphoma Group (GELTAMO, Grupo Español de Linfomas y Trasplante Autólogo de MédulaÓsea) supports the ethical obligation of responsible sharing of data from clinical trials. The study Protocol, informed consent form, and amendments of the study Protocol will be provided. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Request may be made to egine@clinic.cat.

Conception and design: Eva Giné, Armando López-Guillermo Provision of study materials or patients: All authors Collection and assembly of data: All authors Data analysis and interpretation: Eva Giné, Xavier Setoain, Sonia Rodríguez, Alejandro Medina-Herrera, Ramón García-Sanz, Ferran Nadeu, Silvia Beá, Elias Campo, Armando López-Guillermo Manuscript writing: All authors Final approval of manuscript: All authors Accountable for all aspects of the work: All authors

Mantle cell lymphoma

A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease

Molecular pathogenesis of mantle cell lymphoma

A gene signature that distinguishes conventional and leukemic nonnodal mantle cell lymphoma helps predict outcome

Genomic and epigenomic insights into the origin, pathogenesis, and clinical behavior of mantle cell lymphoma subtypes

Outcome of deferred initial therapy in mantle-cell lymphoma

Real world data on primary treatment for mantle cell lymphoma: A Nordic Lymphoma Group observational study

Deferred therapy is associated with improved overall survival in patients with newly diagnosed mantle cell lymphoma

Observation as the initial management strategy in patients with mantle cell lymphoma

Deferred treatment is a safe and viable option for selected patients with mantle cell lymphoma

Clinical presentation determines selection of patients for initial observation in mantle cell lymphoma

40% of females with mantle cell lymphoma are managed with initial observation: Results from the MCL biobank observational study

Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma

Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: A single-centre, open-label, phase 2 trial

Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): A multicentre, open-label, singlearm, phase 2 trial

Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma

Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: A phase 1/ 2 trial

Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL)

Five year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma

Ibrutinib with rituximab in first-line treatment of older patients with mantle cell lymphoma

Minimal residual disease detection in mantle cell lymphoma: Technical aspects and clinical relevance

Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 concerted action BMH4-CT98-3936

Next-generation sequencing technology to identify minimal residual disease in lymphoid malignancies

Newly diagnosed and relapsed mantle cell lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up

TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy

DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I 5 Immediate Family Member, Inst 5 My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)

Expenses: Gilead, Kite Pharma Fátima de la Cruz Honoraria: BeiGene, Takeda, Kyowa Kirin International, AbbVie, Janssen, AstraZeneca Spain Consulting or Advisory Role: BeiGene, EUSA Pharma

AbbVie Alejandro Martín García-Sancho Honoraria

Novartis Travel, Accommodations, Expenses: Janssen, EUSA Pharma Adolfo de la Fuente Honoraria: BSM, AbbVie, Astellas Pharma, Incyte, Pfizer Consulting or Advisory Role: BMS Research Funding: Novartis

General Electric Consulting or Advisory Role: Qbiotech, Lemer Pax Speakers' Bureau: Lemer Pax Patents, Royalties, Other Intellectual Property: Patent and Royalties with the medical device Epijet with the company Lemer Pax Travel, Accommodations, Expenses: Takeda, General Electric Amanda Rotger Employment: ITM Oncologics Honoraria: ITM Oncologics, AAA HealthCare Travel, Accommodations, Expenses: ITM Oncologics Alejandro Medina Herrera Research Funding: Janssen Travel, Accommodations, Expenses: Diagnostica Longwood Ramón García Sanz Honoraria: Janssen, Takeda, Amgen, BeiGene, Novartis, Astellas Pharma Consulting or Advisory Role: Janssen Research Funding: Gilead Sciences (Inst), Incyte (Inst), Astellas Pharma Patents, Royalties, Other Intellectual Property: BIOMED 2 primers (Inst) Travel, Accommodations, Expenses: Janssen, Takeda (I) Other Relationship: Spanish Society of Hematology (SEHH) Ferran Nadeu Honoraria: Janssen Elías Campo Honoraria: EUSA Pharma, AstraZeneca Consulting or Advisory Role: Illumina, AbbVie Patents, Royalties, Other Intellectual Property: Author on a patent licensed to NanoString Technologies Armando López-Guillermo Honoraria: Roche Consulting or Advisory Role

The authors would like to thank the patients and their families, and study investigators and coordinators-among them, Carlos Grande, Lucia Palacios, and Silvia Ruíz-for their contribution to the study. Partial support of biological and MRD studies was obtained from grants Instituto de Salud Carlos III (ISCIII) PI19/00887 (to A.L.-G. and E.G.) and PI17/ 01061 (to S.B.), Fundació La Marató de TV3 grant 201904-30 (to S.B.), Ministerio de Ciencia e Innovación (MCI) RTI2018-094274-B-I00 (to E.C.), National Institutes of Health (NIH) 1P01CA229100 (to E.C.) and FEDER: European Regional Development Fund "Una manera de hacer Europa" (to E.C. and S.B.). A personal grant FEHH-Janssen 2021 to Alejandro Medina-Herrera from Fundación Española de Hematología y Hemoterapia is acknowledged. E.C. is an ICREA Academia Researcher.